La polipíldora cardiovascular, desarrollada por el Centro Nacional de Investigaciones Cardiovasculares (CNIC) y Ferrer, acaba de ser incluida por la OMS en la lista de medicamentos esenciales (EML). Incluye 3 principios activos (ácido acetil salicílico, ramipril y atorvastatina) y ha demostrado ser eficaz en la prevención de eventos cardiovasculares tras un ataque al corazón, disminuyendo la mortalidad por causas cardiovasculares en un 33%, según el estudio SECURE, cuyos resultados publicó en 2022 The New England Journal of Medicine (NEJM).
|
etiquetas: polipíldora cardiovascular , oms , corazón , medicamento esencial , cnic , eml 
- CNIC: www.cnic.es/es/noticias/organizacion-mundial-salud-incluye-polipildora
- Public Health Research Institute (x2): www.phri.ca/eml/ , www.phri.ca/collaborations/polypills-for-cvd-prevention/
- World Heart Federation: world-heart-federation.org/news/world-heart-federation-welcomes-landma
- Infosalus (ESP): www.infosalus.com/actualidad/noticia-oms-incluye-polipildora-cardiovas
- Wikis (x3): en.wikipedia.org/wiki/Polypill , en.wikipedia.org/wiki/Combination_drug , en.wikipedia.org/wiki/WHO_Model_List_of_Essential_Medicines#Cardiovasc
- OMS (List of Essential Medicines (EML)): list.essentialmeds.org/ ("...in the process of being updated to include the 2023 recommendations")
- OMS (comunicado): www.who.int/news/item/26-07-2023-who-endorses-landmark-public-health-d
--> Lo relevante está en el bloque "Cardiovascular medicines":
"Fixed-dose combinations of multiple medicines (commonly called ‘polypills’) for the prevention of diseases of the heart and blood vessels, notably cholesterol-lowering agents with one or more blood pressure lowering agents with and without acetylsalicylic acid (aspirin) have been added to the EML for the first time. Based on recommendations by previous EML Expert Committees, scientists from multiple countries conducted milestone trials confirming the benefit of these combinations for both primary and secondary prevention of heart disease."